Trends in Pharmacological Sciences

Article	Citations
Network pharmacology: curing causal mechanisms instead of treating symptoms	444
Organ-on-a-Chip: A New Paradigm for Drug Development	313
NLRP3 and pyroptosis blockers for treating inflammatory diseases	299
Tryptophan Metabolism as a Pharmacological Target	178
Drug Repurposing for Rare Diseases	145
Metformin and Systemic Metabolism	132
Physiological and pharmacological modulation of BAX	116
Iron metabolism: pathophysiology and pharmacology	114
Metastatic colorectal cancer: mechanisms and emerging therapeutics	114
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics	113
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	112
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery	111
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2	104
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation	104
Update and latest advances in antiretroviral therapy	100
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor	100
Progranulin as a therapeutic target in neurodegenerative diseases	87
Nrf2 for cardiac protection: pharmacological options against oxidative stress	85
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	84
Targeting the Immune System for Ischemic Stroke	84
AKAP Signaling Islands: Venues for Precision Pharmacology	82
Advances and challenges in therapeutic targeting of NRF2	81
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity	80
Recent breakthroughs and future directions in drugging aquaporins	70
Disrupting 3D printing of medicines with machine learning	70

AI-powered therapeutic target discovery	69
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	68
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment	61
Decoding pseudouridine: an emerging target for therapeutic development	60
Computational and artificial intelligence-based methods for antibody development	60
Circulating tumor cells in precision medicine: challenges and opportunities	58
FOXO transcription factors as therapeutic targets in human diseases	55
ER stress in obesity pathogenesis and management	54
Affinity Hydrogels for Protein Delivery	52
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics	52
Carbon Monoxide: from Poison to Clinical Trials	49
3D cell cultures toward quantitative high-throughput drug screening	48
Present and future of microglial pharmacology	48
Structural perspective of class B1 GPCR signaling	46
Biological Cells as Therapeutic Delivery Vehicles	44
High-power screening (HPS) empowered by DNA-encoded libraries	44
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets	41
Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine	40
Membrane protein production and formulation for drug discovery	40
Mouse models of atherosclerosis in translational research	40
Small Molecule Drug Discovery for Neglected Tropical Snakebite	40
Nanodelivery of cGAS-STING activators for tumor immunotherapy	39
Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics	39
Nanocarriers for oral delivery of biologics: small carriers for big payloads	39
CRISPR-based therapeutics: current challenges and future applications	39
Opportunities and challenges for microRNA-targeting therapeutics for epilepsy	39
Cholesterol – the devil you know; ceramide – the devil you don’t	39
14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases	38
Nanomedicine: controlling nanoparticle clearance for translational success	38
Compstatins: the dawn of clinical C3-targeted complement inhibition	38
Autoantibodies as Endogenous Modulators of GPCR Signaling	38
Modulation of T cells by tryptophan metabolites in the kynurenine pathway	37
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic	37
The potential of long noncoding RNA therapies	37
Recent advances in targeting autophagy in cancer	36
Pharmacological tools to target NKCC1 in brain disorders	36
Drug–Exposome Interactions: The Next Frontier in Precision Medicine	36
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	35
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age	35
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display	34
Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs	34
Acid-sensing ion channels as potential therapeutic targets	34
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	34
Can Growth Factors Cure Parkinson’s Disease?	33
Mitochondrial dynamics proteins as emerging drug targets	33
Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors	32
Developing Insulin Delivery Devices with Glucose Responsiveness	32
Single-Cell Techniques and Deep Learning in Predicting Drug Response	32
Targeting galectin-3 in inflammatory and fibrotic diseases	32
Targeting SARS-CoV-2 papain-like protease in the postvaccine era	32

Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions	32
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent	32
Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives	31
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy	31
Engineered antibody fusion proteins for targeted disease therapy	31
Targeting natural killer cells to enhance vaccine responses	31
Targeted protein degrader development for cancer: advances, challenges, and opportunities	30
Targeting intracellular protein–protein interactions with macrocyclic peptides	30
Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future	30
Hypothalamic AMPK as a possible target for energy balance-related diseases	30
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	29
Pharmacogenomics in treatment of depression and psychosis: an update	29
The structure and function of YTHDF epitranscriptomic m6A readers	29
Ferroptosis of immune cells in the tumor microenvironment	29
GABAA receptors as targets for treating affective and cognitive symptoms of depression	29
Histone post-translational modifications as potential therapeutic targets for pain management	29
Electroceuticals in the Gastrointestinal Tract	28
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	28
Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics	28
Bridging the academia-to-industry gap: organ-on-a-chip platforms for safety and toxicology assessment	28
Targeting KNa1.1 channels in KCNT1-associated epilepsy	27
Targeting of Potassium Channels in Cardiac Arrhythmias	27
Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells	26
Countermeasures in organophosphorus intoxication: pitfalls and prospects	25
Interesting antifungal drug targets in the central metabolism of Candida albicans	25
Ferrous Iron-Dependent Pharmacology	25
Engineering ACE2 decoy receptors to combat viral escapability	25
Fragment-based drug design facilitates selective kinase inhibitor discovery	25
Deep mutational scanning for therapeutic antibody engineering	25
Anticancer opportunities at every stage of chemokine function	24
Challenges and opportunities associated with rare-variant pharmacogenomics	24
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	23
Adenosine and inflammation: it's time to (re)solve the problem	23
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	23
Advances in Targeting GIRK Channels in Disease	22
Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives	22
Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells	21
Therapeutic inhibition of ferroptosis in neurodegenerative disease	21
Emerging Therapeutic Applications for Fumarates	21
Microfluidic technologies for drug discovery and development: friend or foe?	21
Supramolecular nanomedicines through rational design of self-assembling prodrugs	20
Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors	20
Emerging strategies for beta cell transplantation to treat diabetes	20
The current toolbox for APOBEC drug discovery	20
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules	20
Targeting complement in neurodegeneration: challenges, risks, and strategies	19
Delivering AAV to the Central Nervous and Sensory Systems	19
BH3 Mimetics in AML Therapy: Death and Beyond?	19
Targeting sialylation to treat central nervous system diseases	18
Unifying mechanism behind the onset of acquired epilepsy	18
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	18
The Potential of 19F NMR Application in GPCR Biased Drug Discovery	18
Omaveloxolone (SkyclarysTM) for patients with Friedreich’s ataxia	17
Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype	17
Subtyping for pancreatic cancer precision therapy	17
Beyond Deterministic Models in Drug Discovery and Development	17
A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2	17
Key metrics to expanding the pipeline of successful antibody–drug conjugates	17
Atypical chemokine receptors: emerging therapeutic targets in cancer	16
Electrophilic Natural Products as Drug Discovery Tools	16
Biomaterials, biological molecules, and polymers in developing vaccines	16
Screening strategies for identifying RNA- and ribonucleoprotein-targeted compounds	16
Channeling Force in the Brain: Mechanosensitive Ion Channels Choreograph Mechanics and Malignancies	16
Obesity pharmacotherapy: incretin action in the central nervous system	15
The pharmacology of the TMEM16A channel: therapeutic opportunities	15
Could dexmedetomidine be repurposed as a glymphatic enhancer?	15
Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension	15
Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders	15
Identifying New Antimigraine Targets: Lessons from Molecular Biology	15
Artificial intelligence-driven drug development against autoimmune diseases	14
Recent advances in the development of therapeutic peptides	14
Human Brain Neuropharmacology: A Platform for Translational Neuroscience	14
Small-molecule correctors and stabilizers to target p53	14
Celiac disease: mechanisms and emerging therapeutics	14
Advancing non-destructive analysis of 3D printed medicines	14
Casimersen for the treatment of Duchenne muscular dystrophy	14
Safety of medicines and vaccines – building next generation capability	14
The structure, function, and pharmacology of MRGPRs	14
siRNA drug Leqvio (inclisiran) to lower cholesterol	14
Peptides as a therapeutic strategy against Klebsiella pneumoniae	14

Therapeutic Targeting of IL-11 for Chronic Lung Disease	13
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	13
Reactive chemistry for covalent probe and therapeutic development	13
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain	13
Monkeypox: potential vaccine development strategies	13
Reprogramming RNA processing: an emerging therapeutic landscape	13
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer	12
PUS7: a targetable epitranscriptomic regulator of glioblastoma growth	12
Proteomic approaches advancing targeted protein degradation	12
‘Channeling’ therapeutic discovery for epileptic encephalopathy through iPSC technologies	12
Structural insights into ligand recognition and activation of angiotensin receptors	12
GPR35: from enigma to therapeutic target	12
Determinants of Use of Biotherapeutics in sub-Saharan Africa	12
Current clinical translation of microbiome medicines	12
Chemogenetic Approaches to Explore the Functions of Free Fatty Acid Receptor 2	11
Current landscape of preclinical models of diabetic cardiomyopathy	11
Targeting Solute Carrier Transporters through Functional Mapping	11
Targeting stressor-induced dysfunctions in protein–protein interaction networks via epichaperomes	11
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	11
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	11
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	11
Gut microbiome-oriented therapy for metabolic diseases: challenges and opportunities towards clinical translation	11
Odorant receptors as potential drug targets	11
Circadian biology to advance therapeutics for mood disorders	11
Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	11
Leveraging aptamers for targeted protein degradation	11
Muscle wasting: emerging pathways and potential drug targets	10
Efflux Limits Tumor Drug Delivery Despite Disrupted BBB	10
Salt-inducible kinases: new players in pulmonary arterial hypertension?	10
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models	10
The rise of epitranscriptomics: recent developments and future directions	10
Wandering beyond small molecules: peptides as allosteric protein modulators	10
Serial Crystallography for Structure-Based Drug Discovery	10
Ganaxolone for management of seizures associated with CDKL5 deficiency disorder	9
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	9
Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins	9
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology	9
Developing novel antifungals: lessons from G protein-coupled receptors	9
Circadian clock-based therapeutics in chronic pulmonary diseases	9
Thapsigargin: key to new host-directed coronavirus antivirals?	9
Mentoring future science leaders to thrive	9
Metabolome-guided genome mining of RiPP natural products	9
Biologics and cardiac disease: challenges and opportunities	9
Rethinking the use of NSAIDs in early acute pain	9
Overcoming proteasome inhibitor resistance in the immunotherapy era	9
TRPC channels as emerging targets for seizure disorders	9
PPAR agonists for the treatment of neuroinflammatory diseases	9
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	9
A smart hospital-driven approach to precision pharmacovigilance	8
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	8
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine	8
Nanotherapeutic-directed approaches to analgesia	8
Ligand selectivity hotspots in serotonin GPCRs	8
The Prognosis of Arthrofibroses: Prevalence, Clinical Shortcomings, and Future Prospects	8
NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	8
Implementing computational methods in tandem with synonymous gene recoding for therapeutic development	7
Emerging epigenetic insights into aging mechanisms and interventions	7
Targeted degradation of extracellular secreted and membrane proteins	7
Targeting sensory neuron GPCRs for peripheral neuropathic pain	7
The consequences of particle uptake on immune cells	7
Trofinetide: a pioneering treatment for Rett syndrome	7
Biophysical and mechanobiological considerations for T-cell-based immunotherapy	7
Beyond the NFAT Horizon: From Cyclosporine A-Induced Adverse Skin Effects to Novel Therapeutics	7
Direct in vivo CAR T cell engineering	7
Futibatinib (Lytgobi) for cholangiocarcinoma	7
Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions	7
Targeting neurological abnormalities in lysosomal storage diseases	7
Lipoxygenases in chronic liver diseases: current insights and future perspectives	7
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	7
Harnessing associative learning paradigms to optimize drug treatment	7
Fluxes for Unraveling Complex Binding Mechanisms	6
Building unconventional G protein-coupled receptors, one block at a time	6
Functional intersections between extracellular vesicles and oncolytic therapies	6
Spatial pharmacology using mass spectrometry imaging	6
A quick guide to networking for scientists	6
A Novel Small Molecule Targets NKCC1 To Restore Synaptic Inhibition	6
Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic targets	6
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities	6
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	6
Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs	6
G-Protein Peptidomimetics Stabilize GPCR Active State Conformations	5
Commensal gut microbiota-based strategies for oral delivery of therapeutic proteins	5
Approaches to address bias in letters of recommendation	5
Context-dependent role of SIRT3 in cancer	5
Chromosome-scale genomes throw light on plant drug biosynthesis	5
ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis	5
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	5
3D models of neurodegeneration: implementation in drug discovery	5
Extrasynaptic therapeutic targets in substance use and stress disorders	5
Covalent fragment approaches targeting non-cysteine residues	4
Lenacapavir (Sunlenca®) for the treatment of HIV-1	4
Targeting solute carriers to modulate receptor–ligand interactions	4
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	4
Advancing small-molecule drug discovery by encoded dual-display technologies	4
Structural snapshot of a β-arrestin-biased receptor	4